Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial, PMID: 33480963
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial, PMID: 32653053
Margetuximab for the treatment of HER2-positive metastatic breast cancer, PMID: 33238772
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma, PMID: 33263418
Margetuximab, PMID: 33355736
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors, PMID: 28119295
Antibodies to watch in 2020, PMID: 31847708
Antibodies to watch in 2021, PMID: 33459118
Margetuximab-cmkb, PMID: 33821931
Novel HER2-targeted therapies for HER2-positive metastatic breast cancer, PMID: 32721042
Margetuximab: First Approval, PMID: 33761116
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies, PMID: 32368385
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options, PMID: 33149670
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217), PMID: 32487035
Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab, PMID: 34159226
Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives, PMID: 33447230
Highlights from the 2019 San Antonio Breast Cancer Symposium, PMID: 32609664
Super Trastuzumab Extends PFS in Late-Line Breast Cancer, PMID: 31175130
What therapies are on the horizon for HER2 positive breast cancer?, PMID: 31448640
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer, PMID: 31656319
Current and Future Management of HER2-Positive Metastatic Breast Cancer, PMID: 34077236
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies, PMID: 34115243
New developments in metastatic breast cancer: integrating recent data into clinical practice, PMID: 24892840
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era, PMID: 34454323
Monoclonal Antibodies in Metastatic Gastro-Esophageal Cancers: An Overview of the Latest Therapeutic Advances., PMID:39940858
Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series., PMID:39220641
Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer., PMID:38994153
Liquid Chromatography Tandem Mass Spectrometric Method for Quantification of Margetuximab in Rat Plasma and Application to a Pharmacokinetic Study., PMID:38332459
An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)., PMID:38288815
Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target., PMID:37958354
New developments and standard of care in the management of advanced gastric cancer., PMID:37952913
Tebotelimab Is Safe and Effective Across Multiple Cancer Types., PMID:37921450
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer., PMID:37878202
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial., PMID:37857711
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?, PMID:37428332
Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer., PMID:37409110
Margetuximab in HER2-positive metastatic breast cancer., PMID:37170847
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma., PMID:37104758
Emerging Targeted Therapies for HER2-Positive Breast Cancer., PMID:37046648
Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report., PMID:36730303
Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy., PMID:36729856
A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer., PMID:36612034
Margetuximab (Margenza) for HER2-positive breast cancer., PMID:36397195
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial., PMID:36332179
Strategies for the treatment of HER2+ advanced breast cancer based on clinical practice in Chinese patients: a roundtable discussion., PMID:38751526
Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study., PMID:38751523
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer., PMID:36279803
Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer., PMID:36272249
Therapeutic landscape of advanced HER2-positive breast cancer in 2022., PMID:36224475
Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China., PMID:36159262
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A., PMID:36029651
Margetuximab conjugated-PEG-PAMAM G4 nano-complex: a smart nano-device for suppression of breast cancer., PMID:35892030
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update., PMID:35640077
Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer., PMID:35509453
Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis., PMID:35418312
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines., PMID:35035535
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review., PMID:35024766
Role of Fcγ receptors in HER2-targeted breast cancer therapy., PMID:34992090
Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021., PMID:34967814
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer., PMID:34916216
Immunotherapy in Breast Cancer: When, How, and What Challenges?, PMID:34829916
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer., PMID:34602823
Clinical development and current role of margetuximab for the treatment of breast cancer., PMID:34586103
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era., PMID:34454323
Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab., PMID:34159226
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies., PMID:34115243
Current and Future Management of HER2-Positive Metastatic Breast Cancer., PMID:34077236
Margetuximab-cmkb., PMID:33821931
FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer., PMID:33767454
Margetuximab: First Approval., PMID:33761116
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial., PMID:33480963
Antibodies to watch in 2021., PMID:33459118
For research use only. Not for human or drug use.
